ABBOTT PARK, Illinois, Aug. 2,
2016 /PRNewswire/ -- Abbott (NYSE: ABT) announced today
the introduction of Alinity™, its harmonized family of
next-generation systems across immunoassay, clinical chemistry,
point of care, hematology, blood and plasma screening and molecular
diagnostics. Each Alinity platform will include a number of
features to help institutions, clinicians and laboratorians better
navigate through a pressure-packed health care environment.
Diagnostic testing guides 70 percent of health care decisions.
Global testing volumes are rising due to an aging population, the
growing management of chronic diseases and increased access to
care. At the same time, health systems are facing pressures to
perform testing as efficiently as possible with limited staff and
space while also reducing costs. Many institutions and labs use
multiple diagnostic platforms, often within a larger health care
network. As they serve more patients and try to improve service
levels with fewer qualified technicians, institutions are looking
for new technologies that can help maximize testing efficiencies
and help better manage resources.
Designed with universal, intuitive interfaces as well as common
software and hardware, Abbott's Alinity systems will have the
ability to work together, providing greater capacity and
simplifying the user experience. Several of the platforms will be
designed to run more tests in less space, generate test results
faster and minimize human errors. By offering a comprehensive
solution that addresses the challenges of using multiple
diagnostics platforms, while continuing to provide quality results
that positively impact patient care, Alinity could potentially
change the industry's testing paradigm.
"Abbott's Alinity portfolio is unprecedented in the industry,"
said Brian Blaser, executive vice
president, Diagnostics Products, Abbott. "With our unified family
of testing instruments, we'll be able to offer more efficiency,
flexibility and confidence to health systems and better help
doctors and nurses get the results they need to improve
decision-making and patient care."
Abbott expects Alinity launches to begin later this year and
continue into 2017.1 The systems are supported by
Abbott's AlinIQ™, the first-of-its-kind, combined professional
services and informatics solution that assists labs in achieving
greater operational productivity with their existing resources.
AlinIQ launched worldwide in April
2016.
DEVELOPED WITH CUSTOMER NEEDS IN MIND
To develop each next-generation platform, Abbott's research and
development teams engaged with thousands of clinicians, scientists,
lab technicians and health care executives. The goal was to better
understand their experiences and learn what is needed to address
the challenges they face, whether in the core laboratory, at the
point of care or in molecular diagnostics.
"Abbott's Alinity systems are being built from the ground up
based on customer insights, using the latest technologies suitable
for testing today and in the future," said Dennis Gilbert, Ph.D., vice president, research
and development, Diagnostics Products, Abbott. "Whether it's
an easy-to-use software interface, running more tests faster or the
ability to run any test at any time, our Alinity platforms are
designed to include these features and more without any compromise
in performance or quality."
The Alinity name is derived from the combination of three key
attributes: alignment, innovation and unity. The Alinity suite of
products is designed to align with customer goals, provide
innovative solutions to address the challenges of today while
anticipating those in the future, and work in unity. The systems
could help institutions, their laboratorians and their health care
providers achieve measurably better performance and help people get
the right diagnosis at the right time.
About Abbott:
At Abbott, we're committed to helping you live your best
possible life through the power of health. For more than 125 years,
we've brought new products and technologies to the world—in
nutrition, diagnostics, medical devices and branded generic
pharmaceuticals—that create more possibilities for more people at
all stages of life. Today, 74,000 of us are working to help people
live not just longer, but better, in the more than 150 countries we
serve.
Connect with us at www.abbott.com, on Facebook at
www.facebook.com/Abbott and on Twitter @AbbottNews and
@AbbottGlobal.
1 Alinity products are currently in development.
Pending appropriate regulatory approvals, each Alinity product may
vary in commercial and geographic availability.
Logo - http://photos.prnewswire.com/prnh/20150928/271488LOGO